The treatment of advanced thyroid cancer has undergone rapid evolution in the last decade,
with multiple kinase inhibitor drug approvals for each subtype of thyroid cancer and a …

Thyroid nodules are very common, and thyroid cancer is currently the fifth leading cancer
diagnosis in women. The American Thyroid Association has led the development and …

This ESMO Clinical Practice Guideline provides updated state-of-the-art recommendations
on management of thyroid cancer (diagnosis, treatment and follow-up), compiled by a …

The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the
management of different types of thyroid carcinoma, including papillary, follicular, Hürthle …

Background Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2,
and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor …

Background Patients with radioactive iodine (131 I)-refractory locally advanced or metastatic
differentiated thyroid cancer have a poor prognosis because of the absence of effective …

Background: Thyroid nodules are a common clinical problem, and differentiated thyroid
cancer is becoming increasingly prevalent. Since the American Thyroid Association's …

Background About half of patients with papillary thyroid cancer have tumours with activating
BRAF V600E mutations. Vemurafenib, an oncogenic BRAF kinase inhibitor approved for …

Activating receptor tyrosine kinase RET (rarranged during transfection) gene alterations
have been identified as oncogenic in multiple malignancies. RET gene rearrangements …

The rearranged during transfection (RET) proto-oncogene was identified in 1985 and, very
soon thereafter, a rearrangement named RET/PTC was discovered in papillary thyroid …